AAVivo

AAVivo, Inc., a spin-off from Virovek, is pioneering precision targeted biotherapeutics with next-generation AAV vectors. Our proprietary CD3scFv-engineered AAV capsids, developed using PACE technology, enable efficient in vivo CAR-T generation through a single intravenous injection. This approach achieves potent CAR-T expansion and complete tumor eradication in preclinical cancer models while eliminating genome-integration risks. Backed by BAC-to-AAV manufacturing and Safety Shield technologies, AAVivo is expanding into autoimmune diseases, delivering safer, scalable, and cost-effective in vivo cell therapies to broader patient populations.